Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 8/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | CTSD | P07339 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18747345 | 0.82 | HPGD (0.41) | L3MBTL1SMN1; SMN2POLBRAB9ATSHR | |
| SCHEMBL12389242 | 0.82 | ATM (0.45) | L3MBTL1SMN1; SMN2POLBRAB9ATSHR | |
| SCHEMBL14440883 | 0.81 | HPGD (0.47) | L3MBTL1SMN1; SMN2POLBRAB9ATSHR | |
| SCHEMBL13225632 | 0.79 | ALDH1A1 (0.46) | L3MBTL1SMN1; SMN2POLBALDH1A1HPGD | |
| SCHEMBL16591612 | 0.79 | L3MBTL1 (0.37) | L3MBTL1USP2SMN1; SMN2POLBRAB9A | |
| SCHEMBL18026620 | 0.79 | L3MBTL1 (0.70) | L3MBTL1USP2SMN1; SMN2FKBP1APOLB | |
| SCHEMBL13221508 | 0.79 | L3MBTL1 (0.59) | L3MBTL1USP2SMN1; SMN2FKBP1APOLB | |
| SCHEMBL5986412 | 0.79 | L3MBTL1 (0.70) | L3MBTL1USP2SMN1; SMN2FKBP1APOLB | |
| SCHEMBL12139844 | 0.78 | TPSAB1 (0.47) | L3MBTL1SMN1; SMN2POLBRAB9AALDH1A1 | |
| SCHEMBL25962133 | 0.78 | L3MBTL1 (0.36) | L3MBTL1USP2SMN1; SMN2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2403846-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-11-02 | — | — | EP | disclosed |
| EP-2403846-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8809341-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299077-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-7683064-B2 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090105251-A1 | Renin inhibitors | TAKEDA SAN DIEGO, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885USP2 3853/4885SMN1; SMN2 2043/4885 |
| US-20070191363-A1 | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | AHR, HCAR2, HCAR1 | L3MBTL1 2188/4885USP2 2350/4885SMN1; SMN2 3167/4885 |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | L3MBTL1 4205/4885USP2 3472/4885SMN1; SMN2 1192/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885USP2 3853/4885SMN1; SMN2 2043/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885USP2 3853/4885SMN1; SMN2 2043/4885 |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | L3MBTL1 2445/4885USP2 3853/4885SMN1; SMN2 2043/4885 |
| US-20090105251-A1 | Renin inhibitors | REN, ACE, AGT | L3MBTL1 4882/4885USP2 1731/4885SMN1; SMN2 4705/4885 |
| US-20090306041-A1 | Inhibitors of Bruton's tyrosine kinase | BTK, SYK, LYN | L3MBTL1 2450/4885USP2 2030/4885SMN1; SMN2 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.